TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression INDs for... | January 23, 2023

Related Keywords

Davidp Southwell ,Tscan Immunobank ,Gavin Macbeath ,Heather Savelle ,Joyce Allaire ,Tscan Therapeutics Inc ,Lifesci Advisors ,Securities Exchange ,Drug Administration ,Company Immunobank ,Nasdaq ,Chief Scientific ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Sci Advisors ,Tscan Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Primary ,End ,Or ,Olid ,Humor ,Supports ,Simultaneous ,Tse ,F ,Multiple ,Crs ,O ,Create ,Multiplexed ,Fell ,Therapies ,Ased ,N ,Target ,La ,Expression ,Nds Tcrx Us89854m1018 ,